ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1836

Embracing a Biopsychosocial Approach to Fibromyalgia-like Symptoms in People with SLE: Insights from the Type 2 SLE Consortium

Jennifer Rogers1, Megan Clowse2 and Amanda Eudy3, 1Duke University, Durham, NC, 2Duke University, Chapel Hill, NC, 3Duke University, Raleigh, NC

Meeting: ACR Convergence 2023

Keywords: Fatigue, fibromyalgia, pain, quality of life, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1827–1839) Fibromyalgia & Other Clinical Pain Syndromes Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with SLE experience distressing fibromyalgia-like symptoms of fatigue, widespread pain, mood disturbance, and brain fog that negatively impact quality of life and are challenging to manage. These symptoms, termed Type 2 SLE, can be related to inflammatory and non-inflammatory etiologies. Studies of fibromyalgia suggest that addressing biopsychosocial factors can improve quality of life. A Type 2 SLE Consortium was created to bring together a multidisciplinary team of patients and clinicians to develop equitable, feasible, and potentially effective approaches to care for people living with Type 2 SLE.

Methods: The Type 2 SLE Consortium included patients meeting ACR/SLICC SLE classification criteria and clinicians who treat chronic pain, insomnia, and mood disorders. The consortium met in 3 group sessions; additionally, each consortium member was invited to complete an individual interview. The sessions were conducted virtually between August 2022-April 2023 and auto-recorded and then transcribed.

Early sessions included a review of the Type 1 & 2 SLE Model, followed by suggestions from Consortium members about the possible etiology, contributing factors, and treatment approaches for fibromyalgia-like symptoms in people with SLE. Rapid qualitative evaluation identified key themes.

Results: The Type 2 SLE Consortium included 2 women with SLE (both Black with SLE duration >15 years) and 18 health professionals (67% female, 89% academic). Expertise was gathered from adult and pediatric rheumatology, integrative medicine, neurology, psychiatry, psychology, palliative care, neuropsychology, medical weight management, sleep, pain, and stress management. The majority (83%) attended at least 1 group meeting and all but 1 member completed the individual session.

The Consortium identified a range of biopsychosocial factors that can predispose, precipitate, and perpetuate Type 2 symptoms such as fear, stress, and trauma (Figure 1).Two main categories of approaches to care were identified: one for providers and the other for patients (Table 2). Key themes consisted of building better therapeutic relationships, adjusting expectations, improving symptom understanding, lifestyle interventions, and multidisciplinary collaboration. Specific guidance for clinicians included active listening, validating symptoms, and using motivational interviewing. Patients with SLE would benefit from setting personal goals, building self-efficacy, pacing, identifying personal factors, and reframing their relationship with symptoms.

Conclusion: Key recommendations from this multi-disciplinary consortium were to individualize treatment based on the biopsychosocial underpinnings driving the symptom burden. The importance of communication, trust, education, and multidisciplinary collaboration was emphasized. Rheumatologists cannot be the sole providers to improve Type 2 SLE symptoms but can encourage patients to partner with others who can provide the necessary care. Our future studies will continue to develop and evaluate holistic approaches to SLE care.

Supporting image 1

Figure 1. Biopsychosocial factors that contribute to fibromyalgia-like symptoms in SLE

Supporting image 2

Table 2. Care delivery and treatment recommendations for clinicians and patients


Disclosures: J. Rogers: Amgen, 2, Ampel Biosolutions, 1, AstraZeneca, 6, Aurinia, 1, Eli Lilly, 1, Exagen, 5, GlaxoSmithKlein(GSK), 2, Immunovant, 2, 5; M. Clowse: Exagen, 5, GlaxoSmithKlein(GSK), 2, 5, Immunovant, 5, UCB, 2, 5; A. Eudy: Amgen, 2, Exagen, 5, GlaxoSmithKlein(GSK), 5, Immunovant, 5, Pfizer, 5.

To cite this abstract in AMA style:

Rogers J, Clowse M, Eudy A. Embracing a Biopsychosocial Approach to Fibromyalgia-like Symptoms in People with SLE: Insights from the Type 2 SLE Consortium [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/embracing-a-biopsychosocial-approach-to-fibromyalgia-like-symptoms-in-people-with-sle-insights-from-the-type-2-sle-consortium/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/embracing-a-biopsychosocial-approach-to-fibromyalgia-like-symptoms-in-people-with-sle-insights-from-the-type-2-sle-consortium/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology